Immunotherapy
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% Excerpt from the Press Release: Excerpt from the Press Release: ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working…
Read More
SZN-1326 is a Fzd5-targeted Wnt-mimetic (SWAP) bi-specific antibody First part of three-part Phase 1/1b trial starts in healthy volunteers Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a clinical-stage company pioneering targeted therapeutics that selectively activate the Wnt pathway for…
Read More
CRB-601 is a highly potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of TGFb in the local tumor microenvironment Additional non-clinical data demonstrates combination benefit across a diverse range of syngeneic models with differential sensitivity to checkpoint inhibition Anti-tumor activity correlates with increases in proliferating CD4+ and CD8+ T-cells as well as the NK…
Read More
– Myeloid dosed MT-101 in a patient with refractory PTCL within 18 months, illustrating the potential of mRNA therapies to help patients sooner and to accelerate Myeloid’s portfolio- – Myeloid achieved an unprecedented, reduced vein-to-vein time of eight days with this patient dosing- – MT-101 represents a new class of non-T cell CAR’s being tested…
Read More
Therapeutic Solutions International Continues Parallel Development of COPD Program in Conjunction with Pivotal Clinical Trial in COVID-19 Excerpt from the Press Release: OCEANSIDE, Calif.–(BUSINESS WIRE)–Therapeutic Solutions International announced today new data demonstrating enhancement of therapeutic activities of the JadiCell™ through induction of a specific cell type called “Myeloid Derived Progenitor Cells”. In a series of…
Read More
Repertoire’s proprietary cell-tethering technology limits systemic toxicity typically associated with use of immunomodulatory IL-12 and allows direct delivery to solid tumors in mouse models Tethered IL-12 repolarizes the tumor microenvironment potentially creating improved conditions for cellular immunotherapies to work effectively Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Repertoire Immune Medicines announced today that Science Advances published preclinical research…
Read More
Excerpt from the Press Release: Quantum Leap Healthcare Collaborative™ (Quantum Leap) and Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the selection of Ambrx’s antibody drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-SPY 2.2…
Read More
Phase 1 trial with cancer-targeting adenovirus enhanced with a TGFβ Trap continues to investigate safety and anti-tumor activity in patients with advanced cancer Excerpt from the Press Release: TORREY PINES, Calif., April 21, 2022 /PRNewswire/ — EpicentRx Inc., a leading-edge immunotherapy company using groundbreaking science to treat cancer and multiple inflammatory-driven diseases, today announced the initiation of the…
Read More
IO-106 is the third development candidate arising from Immune-Onc’s pioneering pipeline of myeloid checkpoint inhibitors, a new class of immunotherapy that aims to overcome immune resistance in cancer The Company will present a scientific poster at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic Approach Workshop Excerpt from the Press Release:…
Read More
Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows NeutralizingActivity Against 2 Strains of the COVID-19 Virus The Goal to Provide Broader Range Protection within a Highly Flexible PlatformAppears to Show Promise Excerpt from the Press Release: LAWRENCEVILLE, N.J., April 21, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today presented…
Read More